A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy
Phase of Trial: Phase I
Latest Information Update: 15 Aug 2018
At a glance
- Drugs HPN 424 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Harpoon Therapeutics
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.
- 22 Jun 2018 Status changed from planning to not yet recruiting.
- 25 May 2017 According to a Harpoon Therapeutics media release, the company expects to enter phase I clinical trials in 2018.